Roche, Daiichi expect early FDA approval for Melanoma Drug Vemurafenib
Information gathered from close sources reveal that the US regulatory agency might approve an oral BRAF inhibitor vemurafenib jointly developed
Read more
Clinical Research Society
International Society for Clinical Research and Translational Medicine